Your daily dose of news, notes and links from around Kansas University.

• I did some poking around the other day using data from the U.S. Department of Education’s Equity in Athletics report.

There are all kinds of goodies in the report, but I’ll take time to share this one that I found. It lists revenues and expenses that the athletics department reported on each sport in 2009.

I always hear anecdotally that football is the big money-maker in college athletics, and men’s basketball can’t keep up.

Football took in nearly $17.9 million in revenues, and spent $16.3 million, for about a $1.5 million profit.

And men’s basketball? It spent just under $11 million and took in more than $16.1 million, for a more than $5 million profit.

KU football, by the way, edged out Kansas State’s program in overall football revenues in 2009. K-State managed just more than $17.5 million that year.

Numbers are fun. If you do some digging yourself in the report and find something else cool, feel free to let me know. It’ll be kind of like Heard on the Hill’s own little search through Sarah Palin’s emails.

• The KU School of Law has released its salary data for graduates in the Class of 2010, according to a blog post from the school.

And, probably somewhat predictably, the salaries are down from last year’s class.

For the Class of 2010, the mean salary for a job that requires bar passage is $66,042, down from $70,754 for the Class of 2009.

The median salary, by the way, for 2010 grads is $57,000, showing that graduates still do have a few very high-paying gigs that are dragging the averages up.

Also probably predictably, graduates reporting taking jobs at large firms with more than 101 attorneys are also down, from 23 in 2009 to 19 in 2010.

We don’t yet have national data with which to compare KU’s numbers.

• A KU researcher has contributed to a study that uses a new combination of drugs to attack the hepatitis C virus.

Steven Weinman, a KU Medical Center professor of internal medicine, is listed as a co-author on the study, which was led by researchers from the University of Leeds in the United Kingdom.

The study, published in the journal Hepatology, shows how two prototype small molecule drugs can attack different parts of the hepatitis C virus.

The virus can cause liver disease, cancer and death.

The new treatment would attack the virus directly instead of current drugs, which are used to boost a patient’s immune system.

• Tips for Heard on the Hill boost my immune system. Help make me well by sending them to me at ahyland@ljworld.com.